Abstract：
Predictive biomarkers for nivolumab in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC) have not yet been established.
The tumor proportion score (TPS), combined positive score (CPS), and soluble forms of programmed cell death ligand-1 (PD-L1) and programmed cell death ligand-2 (PD-L2) were retrospectively analyzed in patients with RMHNSCC treated with nivolumab.
The positivity rates for TPS (PD-L1), CPS (PD-L1), TPS (PD-L2), and CPS (PD-L2) were 73.8%, 78.2%, 56.4%, and 78.2%, respectively. Patients with high TPS (PD-L1), CPS (PD-L1), or CPS (PD-L1 and PD-L2) showed significantly prolonged progression-free survival. Favorable overall survival was associated with high CPS (PD-L1 and PD-L2) and low soluble PD-L1 and PD-L2 levels. The expressions of tissue and soluble PD-L1/2 were not correlated.
Our study revealed that compared to PD-L1 expression alone, dual expression of PD-L1 and PD-L2 in tissue or soluble form could be feasible biomarkers in patients with RMHNSCC who received nivolumab.
The tumor proportion score (TPS), combined positive score (CPS), and soluble forms of programmed cell death ligand-1 (PD-L1) and programmed cell death ligand-2 (PD-L2) were retrospectively analyzed in patients with RMHNSCC treated with nivolumab.
The positivity rates for TPS (PD-L1), CPS (PD-L1), TPS (PD-L2), and CPS (PD-L2) were 73.8%, 78.2%, 56.4%, and 78.2%, respectively. Patients with high TPS (PD-L1), CPS (PD-L1), or CPS (PD-L1 and PD-L2) showed significantly prolonged progression-free survival. Favorable overall survival was associated with high CPS (PD-L1 and PD-L2) and low soluble PD-L1 and PD-L2 levels. The expressions of tissue and soluble PD-L1/2 were not correlated.
Our study revealed that compared to PD-L1 expression alone, dual expression of PD-L1 and PD-L2 in tissue or soluble form could be feasible biomarkers in patients with RMHNSCC who received nivolumab.
摘要：
背景：在复发性或转移性头颈部鳞状细胞癌（RMHNSCC）中，nivolumab的预测性生物标志物尚未建立。
方法：肿瘤比例评分（TPS），综合阳性评分(CPS)，在接受纳武单抗治疗的RMHNSCC患者中,回顾性分析了程序性细胞死亡配体-1(PD-L1)和程序性细胞死亡配体-2(PD-L2)的可溶性形式.
结果：TPS（PD-L1）的阳性率，CPS（PD-L1），TPS（PD-L2），CPS（PD-L2）为73.8%，78.2%,56.4%,78.2%,分别。高TPS（PD-L1）患者，CPS（PD-L1），或CPS(PD-L1和PD-L2)显示无进展生存期显著延长。良好的总生存率与高CPS（PD-L1和PD-L2）和低可溶性PD-L1和PD-L2水平相关。组织和可溶性PD-L1/2的表达无相关性。
结论：我们的研究表明，与单独的PD-L1表达相比，在接受纳武单抗治疗的RMHNSCC患者中,组织或可溶性形式的PD-L1和PD-L2双重表达可能是可行的生物标志物.
方法：肿瘤比例评分（TPS），综合阳性评分(CPS)，在接受纳武单抗治疗的RMHNSCC患者中,回顾性分析了程序性细胞死亡配体-1(PD-L1)和程序性细胞死亡配体-2(PD-L2)的可溶性形式.
结果：TPS（PD-L1）的阳性率，CPS（PD-L1），TPS（PD-L2），CPS（PD-L2）为73.8%，78.2%,56.4%,78.2%,分别。高TPS（PD-L1）患者，CPS（PD-L1），或CPS(PD-L1和PD-L2)显示无进展生存期显著延长。良好的总生存率与高CPS（PD-L1和PD-L2）和低可溶性PD-L1和PD-L2水平相关。组织和可溶性PD-L1/2的表达无相关性。
结论：我们的研究表明，与单独的PD-L1表达相比，在接受纳武单抗治疗的RMHNSCC患者中,组织或可溶性形式的PD-L1和PD-L2双重表达可能是可行的生物标志物.
